VEGFA GENE variation influences hallucinations and frontotemporal morphology in psychotic disorders

a B-SNIP study

Paulo Lizano, Olivia Lutz, George Ling, Jaya Padmanabhan, Neeraj Tandon, John Sweeney, Carol Tamminga, Godfrey Pearlson, Gualberto Ruaño, Mohan Kocherla, Andreas Windemuth, Brett Clementz, Elliot Gershon, Matcheri Keshavan

Research output: Contribution to journalArticle

Abstract

Vascular endothelial growth factor A (VEGFA) dysfunction may contribute to a number of pathological processes that characterize psychotic disorders. However, the influence of VEGFA gene variants on clinical and neuroimaging phenotypes in psychotic disorders has yet to be shown. In the present study, we examined whether different VEGFA gene variants influence psychosis risk, symptom severity, cognition, and brain volume. The study group included 480 probands (Bipolar I disorder with psychosis, n = 205; Schizoaffective disorder, n = 112; Schizophrenia, n = 163) and 126 healthy controls that were recruited across six sites in the B-SNIP consortium. VEGFA variants identified for analysis (rs699947, rs833070, and rs2146323) were quantified via SNP chip array. We assessed symptoms and cognition using standardized clinical and neuropsychological batteries. The dorsolateral prefrontal cortex (DLPFC), medial temporal lobe, and hippocampal volumes were quantified using FreeSurfer. In our sample, VEGFA rs2146323 A- carriers showed reduced odds of being a proband (p = 0.037, OR = 0.65, 95% CI = 0.43–0.98) compared to noncarriers, but not for rs699947 or rs833070. In probands, rs2146323 A- carriers demonstrated fewer hallucinations (p = 0.035, Cohen’s d = 0.194), as well as significantly greater DLPFC (p < 0.05, Cohen’s d = −0.21) and parahippocampal volumes (p < 0.01, Cohen’s d = −0.27). No clinical or neuroimaging associations were identified for rs699947 or rs833070. In general, we found that the three SNPs exhibited several significant negative relationships between psychosis symptoms and brain structure. In the probands and control groups, positive relationships were identified between several cognitive and brain volume measures. The findings suggest VEGFA effects in the DLPFC and hippocampus found in animals may also extend to humans. VEGFA variations may have important implications in identifying dimensional moderators of function that could be targeted through VEGFA-mediated interventions.

Original languageEnglish (US)
Article number215
JournalTranslational Psychiatry
Volume8
Issue number1
DOIs
StatePublished - Dec 1 2018

Fingerprint

Hallucinations
Psychotic Disorders
Vascular Endothelial Growth Factor A
Prefrontal Cortex
Neuroimaging
Cognition
Single Nucleotide Polymorphism
Brain
Pathologic Processes
Temporal Lobe
Bipolar Disorder
Genes
Hippocampus
Schizophrenia
Phenotype
Control Groups

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience
  • Biological Psychiatry

Cite this

VEGFA GENE variation influences hallucinations and frontotemporal morphology in psychotic disorders : a B-SNIP study. / Lizano, Paulo; Lutz, Olivia; Ling, George; Padmanabhan, Jaya; Tandon, Neeraj; Sweeney, John; Tamminga, Carol; Pearlson, Godfrey; Ruaño, Gualberto; Kocherla, Mohan; Windemuth, Andreas; Clementz, Brett; Gershon, Elliot; Keshavan, Matcheri.

In: Translational Psychiatry, Vol. 8, No. 1, 215, 01.12.2018.

Research output: Contribution to journalArticle

Lizano, P, Lutz, O, Ling, G, Padmanabhan, J, Tandon, N, Sweeney, J, Tamminga, C, Pearlson, G, Ruaño, G, Kocherla, M, Windemuth, A, Clementz, B, Gershon, E & Keshavan, M 2018, 'VEGFA GENE variation influences hallucinations and frontotemporal morphology in psychotic disorders: a B-SNIP study', Translational Psychiatry, vol. 8, no. 1, 215. https://doi.org/10.1038/s41398-018-0271-y
Lizano, Paulo ; Lutz, Olivia ; Ling, George ; Padmanabhan, Jaya ; Tandon, Neeraj ; Sweeney, John ; Tamminga, Carol ; Pearlson, Godfrey ; Ruaño, Gualberto ; Kocherla, Mohan ; Windemuth, Andreas ; Clementz, Brett ; Gershon, Elliot ; Keshavan, Matcheri. / VEGFA GENE variation influences hallucinations and frontotemporal morphology in psychotic disorders : a B-SNIP study. In: Translational Psychiatry. 2018 ; Vol. 8, No. 1.
@article{c8641def574b4ad2943096519e1c00d3,
title = "VEGFA GENE variation influences hallucinations and frontotemporal morphology in psychotic disorders: a B-SNIP study",
abstract = "Vascular endothelial growth factor A (VEGFA) dysfunction may contribute to a number of pathological processes that characterize psychotic disorders. However, the influence of VEGFA gene variants on clinical and neuroimaging phenotypes in psychotic disorders has yet to be shown. In the present study, we examined whether different VEGFA gene variants influence psychosis risk, symptom severity, cognition, and brain volume. The study group included 480 probands (Bipolar I disorder with psychosis, n = 205; Schizoaffective disorder, n = 112; Schizophrenia, n = 163) and 126 healthy controls that were recruited across six sites in the B-SNIP consortium. VEGFA variants identified for analysis (rs699947, rs833070, and rs2146323) were quantified via SNP chip array. We assessed symptoms and cognition using standardized clinical and neuropsychological batteries. The dorsolateral prefrontal cortex (DLPFC), medial temporal lobe, and hippocampal volumes were quantified using FreeSurfer. In our sample, VEGFA rs2146323 A- carriers showed reduced odds of being a proband (p = 0.037, OR = 0.65, 95{\%} CI = 0.43–0.98) compared to noncarriers, but not for rs699947 or rs833070. In probands, rs2146323 A- carriers demonstrated fewer hallucinations (p = 0.035, Cohen’s d = 0.194), as well as significantly greater DLPFC (p < 0.05, Cohen’s d = −0.21) and parahippocampal volumes (p < 0.01, Cohen’s d = −0.27). No clinical or neuroimaging associations were identified for rs699947 or rs833070. In general, we found that the three SNPs exhibited several significant negative relationships between psychosis symptoms and brain structure. In the probands and control groups, positive relationships were identified between several cognitive and brain volume measures. The findings suggest VEGFA effects in the DLPFC and hippocampus found in animals may also extend to humans. VEGFA variations may have important implications in identifying dimensional moderators of function that could be targeted through VEGFA-mediated interventions.",
author = "Paulo Lizano and Olivia Lutz and George Ling and Jaya Padmanabhan and Neeraj Tandon and John Sweeney and Carol Tamminga and Godfrey Pearlson and Gualberto Rua{\~n}o and Mohan Kocherla and Andreas Windemuth and Brett Clementz and Elliot Gershon and Matcheri Keshavan",
year = "2018",
month = "12",
day = "1",
doi = "10.1038/s41398-018-0271-y",
language = "English (US)",
volume = "8",
journal = "Translational Psychiatry",
issn = "2158-3188",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - VEGFA GENE variation influences hallucinations and frontotemporal morphology in psychotic disorders

T2 - a B-SNIP study

AU - Lizano, Paulo

AU - Lutz, Olivia

AU - Ling, George

AU - Padmanabhan, Jaya

AU - Tandon, Neeraj

AU - Sweeney, John

AU - Tamminga, Carol

AU - Pearlson, Godfrey

AU - Ruaño, Gualberto

AU - Kocherla, Mohan

AU - Windemuth, Andreas

AU - Clementz, Brett

AU - Gershon, Elliot

AU - Keshavan, Matcheri

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Vascular endothelial growth factor A (VEGFA) dysfunction may contribute to a number of pathological processes that characterize psychotic disorders. However, the influence of VEGFA gene variants on clinical and neuroimaging phenotypes in psychotic disorders has yet to be shown. In the present study, we examined whether different VEGFA gene variants influence psychosis risk, symptom severity, cognition, and brain volume. The study group included 480 probands (Bipolar I disorder with psychosis, n = 205; Schizoaffective disorder, n = 112; Schizophrenia, n = 163) and 126 healthy controls that were recruited across six sites in the B-SNIP consortium. VEGFA variants identified for analysis (rs699947, rs833070, and rs2146323) were quantified via SNP chip array. We assessed symptoms and cognition using standardized clinical and neuropsychological batteries. The dorsolateral prefrontal cortex (DLPFC), medial temporal lobe, and hippocampal volumes were quantified using FreeSurfer. In our sample, VEGFA rs2146323 A- carriers showed reduced odds of being a proband (p = 0.037, OR = 0.65, 95% CI = 0.43–0.98) compared to noncarriers, but not for rs699947 or rs833070. In probands, rs2146323 A- carriers demonstrated fewer hallucinations (p = 0.035, Cohen’s d = 0.194), as well as significantly greater DLPFC (p < 0.05, Cohen’s d = −0.21) and parahippocampal volumes (p < 0.01, Cohen’s d = −0.27). No clinical or neuroimaging associations were identified for rs699947 or rs833070. In general, we found that the three SNPs exhibited several significant negative relationships between psychosis symptoms and brain structure. In the probands and control groups, positive relationships were identified between several cognitive and brain volume measures. The findings suggest VEGFA effects in the DLPFC and hippocampus found in animals may also extend to humans. VEGFA variations may have important implications in identifying dimensional moderators of function that could be targeted through VEGFA-mediated interventions.

AB - Vascular endothelial growth factor A (VEGFA) dysfunction may contribute to a number of pathological processes that characterize psychotic disorders. However, the influence of VEGFA gene variants on clinical and neuroimaging phenotypes in psychotic disorders has yet to be shown. In the present study, we examined whether different VEGFA gene variants influence psychosis risk, symptom severity, cognition, and brain volume. The study group included 480 probands (Bipolar I disorder with psychosis, n = 205; Schizoaffective disorder, n = 112; Schizophrenia, n = 163) and 126 healthy controls that were recruited across six sites in the B-SNIP consortium. VEGFA variants identified for analysis (rs699947, rs833070, and rs2146323) were quantified via SNP chip array. We assessed symptoms and cognition using standardized clinical and neuropsychological batteries. The dorsolateral prefrontal cortex (DLPFC), medial temporal lobe, and hippocampal volumes were quantified using FreeSurfer. In our sample, VEGFA rs2146323 A- carriers showed reduced odds of being a proband (p = 0.037, OR = 0.65, 95% CI = 0.43–0.98) compared to noncarriers, but not for rs699947 or rs833070. In probands, rs2146323 A- carriers demonstrated fewer hallucinations (p = 0.035, Cohen’s d = 0.194), as well as significantly greater DLPFC (p < 0.05, Cohen’s d = −0.21) and parahippocampal volumes (p < 0.01, Cohen’s d = −0.27). No clinical or neuroimaging associations were identified for rs699947 or rs833070. In general, we found that the three SNPs exhibited several significant negative relationships between psychosis symptoms and brain structure. In the probands and control groups, positive relationships were identified between several cognitive and brain volume measures. The findings suggest VEGFA effects in the DLPFC and hippocampus found in animals may also extend to humans. VEGFA variations may have important implications in identifying dimensional moderators of function that could be targeted through VEGFA-mediated interventions.

UR - http://www.scopus.com/inward/record.url?scp=85054777935&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054777935&partnerID=8YFLogxK

U2 - 10.1038/s41398-018-0271-y

DO - 10.1038/s41398-018-0271-y

M3 - Article

VL - 8

JO - Translational Psychiatry

JF - Translational Psychiatry

SN - 2158-3188

IS - 1

M1 - 215

ER -